Therapeutic applications of curcumin for patients with pancreatic cancer.
Author:
- 28 July 2014
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 20 (28) , 9384-91
Abstract
A number of preclinical studies have demonstrated anticancer effects for curcumin in various types of tumors, including pancreatic cancer. Curcumin has anticancer effects both alone and in combination with other anticancer drugs (e.g., gemcitabine, 5-fluorouracil, and oxaliplatin), and it has been shown to modulate a variety of molecular targets in preclinical models, with more than 30 molecular targets identified to date. Of these various molecules, NF-κB is thought to be one of the primary targets of curcumin activity. Based on these promising preclinical results, several research groups, including our own, have progressed to testing the anticancer effects of curcumin in clinical trials; however, the poor bioavailability of this agent has been the major challenge for its clinical application. Despite the ingestion of gram-level doses of curcumin, plasma curcumin levels remain at low (ng/mL) levels in patients, which is insufficient to yield the anticancer benefits of curcumin. This problem has been solved by the development of highly bioavailable forms of curcumin (THERACURMIN), and higher plasma curcumin levels can now be achieved without increased toxicity in patients with pancreatic cancer. In this article, we review possible therapeutic applications of curcumin in patients with pancreatic cancer.Keywords
This publication has 72 references indexed in Scilit:
- Novel Curcumin-Loaded Magnetic Nanoparticles for Pancreatic Cancer TreatmentMolecular Cancer Therapeutics, 2013
- Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cellsCancer Chemotherapy and Pharmacology, 2010
- Development of multiple-layer polymeric particles for targeted and controlled drug deliveryNanomedicine: Nanotechnology, Biology and Medicine, 2010
- Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy.2009
- Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer CellsCancer Research, 2009
- Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFκBCarcinogenesis, 2007
- HIGHLY ACTIVE ANTICANCER CURCUMIN ANALOGUES2007
- Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcuminJournal of Pharmaceutical and Biomedical Analysis, 2006
- Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response RateJournal of Clinical Oncology, 2004
- Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297Journal of Clinical Oncology, 2002